Lysosomal biogenesis and function in African trypanosomes

非洲锥虫的溶酶体生物发生和功能

• 批准号: 8235786
• 负责人: James D. Bangs
• 金额: $ 36.74万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8235786
• 关键词: Africa South of the Sahara; African; African Trypanosomiasis; Antigen-Antibody Complex; Attention; Belief; Binding; Biogenesis; Bioinformatics; Biological Process; Biology; Bite; Blood Circulation; Cattle; Cell surface; Cells; Chloride Channels; Chloride Ion; Chlorides; Country; Disease; Eflornithine; Equilibrium; Eukaryotic Cell; Event; Evolution; Foundations; Funding; Future; Golgi Apparatus; Human; Human Activities; Immune; Infection; Intervention; Investigation; Knock-out; Life Cycle Stages; Livestock; Location; Lysosomes; Lytic; Melarsoprol; Membrane Glycoproteins; Membrane Proteins; Monomeric GTP-Binding Proteins; N-terminal; Neuraxis; Nutritional; Organelles; Parasites; Pathogenesis; Pathway interactions; Penetration; Peptide Hydrolases; Pharmaceutical Preparations; Physiology; Process; Protein Family; Protozoa; RNA Interference; Recycling; Regimen; Reporter; Resistance; Risk; Role; Route; Serum; Signal Transduction; Sorting - Cell Movement; Staging; Therapeutic; Transport Vesicles; Trypanosoma; Trypanosoma brucei brucei; Tsetse Flies; Vaccination; Variant; Work; base; drug development; human disease; killings; mutant; nagana; pathogen; public health relevance; receptor; repository; trafficking; trait; transmission process; vector

DESCRIPTION (provided by applicant): African trypanosomes (Trypanosoma brucei ssp.) are parasitic protozoa that cause human African trypanosomiasis (HAT, sleeping sickness), as well as nagana in cattle and other livestock. These diseases have devastating impact throughout sub-Saharan Africa where the tsetse fly vector is found. Some 60 million people in 36 countries are at risk of tsetse bite, and therefore of transmission, and as recently as 2000 the WHO estimated that there were 300,000 or more new infections per year. Only a handful of drugs are in use for treating HAT, the best of which (eflornithine) is expensive and requires a difficult regimen, the worst of which (melarsoprol) kills up to 10% of recipients. Infection is inevitably fatal without intervention, and since vaccination is not an option there is a critical need for new drug development. Toward this end a better understanding of the basic biology of the parasite is essential, particularly of processes that may be amenable to therapeutics. Such a process is the biogenesis of the parasite lysosome because it impacts the host- pathogen balance in multiple ways. Expression of lysosomal activities is differentially regulated through the trypanosome life cycle [1], and there are stage specific differences in the biosynthetic trafficking of essential lysosomal components [2]. The lysosome is the final repository of endocytic cargo acquired from host serum for nutritional purposes [3], as well as for potentially lytic immune complexes removed from the cell surface [4]. Release of the lysosomal protease TbCatL (trypanopain) is a factor in the signature event of human infection, penetration of the central nervous system [5]. Lysosomal physiology is critical to the activity of an innate human serum resistance trait, trypanolytic factor, which limits the host range of Trypanosoma species [6]. And finally, lysosomal hydrolytic activities have drawn considerable attention as potential chemotherapeutic targets [7]. Lysosomal biogenesis and function in trypanosomes are intimately related to the larger topic of secretory/endocytic trafficking. Much progress has been made in defining these processes, particularly regarding export and recycling of the bloodstream stage variant surface glycoprotein. However, little is known about pathways, either biosynthetic or endocytic, leading to the lysosome. In the previous funding period we initiated studies based on a single lysosomal membrane protein p67. In this proposal we intend to build on our previous studies of p67 (Aim #1), but also to extend our focus to other components of the lysosome (Aims #2 & 3). The purpose of this work is to enlarge our understanding of this critical aspect of basic trypanosome biology. It is our firm belief that this effort will help lay the foundation for future drug development, and will also illuminate not just the differences, but also the similarities of cell biological processes common the full range of eukaryotic evolution. PUBLIC HEALTH RELEVANCE: African trypanosomes (Trypanosoma brucei ssp.) are parasitic protozoa that cause human African trypanosomiasis (HAT, sleeping sickness), as well as nagana in cattle and other livestock. Current drugs are toxic and vaccination is not an option, consequently new chemotherapeutic targets are needed. The lysosome is a digestive organelle critical for parasite viability and pathogenesis. Basic studies of the biogenesis and function of the lysosome will provide a foundation for subsequent parasite-specific drug development.

描述（由申请人提供）：非洲锥虫（布鲁氏锥虫）是一种寄生原虫，可引起人类非洲锥虫病（HAT，昏睡病），以及牛和其他牲畜的那加纳病。这些疾病对整个发现采采蝇媒介的撒哈拉以南非洲地区造成毁灭性影响。36个国家约有6000万人面临采采蝇叮咬和传播的风险，就在2000年，世卫组织估计每年有30万或更多的新感染病例。目前只有少数几种药物用于治疗HAT，其中最好的药物（依氟鸟氨酸）价格昂贵，需要一个复杂的治疗方案，最糟糕的药物（美拉胂醇）可导致10%的患者死亡。如果不进行干预，感染不可避免地是致命的，而且由于不能选择接种疫苗，因此迫切需要开发新药。为了实现这一目标，更好地了解寄生虫的基本生物学是必不可少的，特别是那些可能适合治疗的过程。这一过程是寄生虫溶酶体的生物发生过程，因为它以多种方式影响宿主与病原体的平衡。在锥虫生命周期[1]中，溶酶体活性的表达受到不同的调节，并且在必需溶酶体成分[2]的生物合成运输中存在不同阶段的差异。溶酶体是从宿主血清中获得的内吞货物的最终储存库，用于营养目的[3]，以及从细胞表面去除的潜在的溶解免疫复合物[4]。溶酶体蛋白酶TbCatL（锥虫蛋白酶）的释放是人类感染穿透中枢神经系统[5]的标志性事件的一个因素。溶酶体生理对先天的人类血清抗性性状——锥虫溶解因子的活性至关重要，它限制了锥虫物种[6]的宿主范围。最后，溶酶体水解活性作为潜在的化疗靶点已经引起了相当大的关注。锥虫体内溶酶体的生物发生和功能与分泌/内吞运输密切相关。在定义这些过程方面已经取得了很大进展，特别是关于血流阶段变体表面糖蛋白的输出和再循环。然而，对于导致溶酶体的生物合成或内吞途径所知甚少。在之前的资助期内，我们启动了基于单个溶酶体膜蛋白p67的研究。在本提案中，我们打算建立在我们以前对p67的研究（目标#1）的基础上，但也将我们的重点扩展到溶酶体的其他成分（目标#2和3）。这项工作的目的是扩大我们对基本锥虫生物学这一关键方面的理解。我们坚信，这一努力将有助于为未来的药物开发奠定基础，并将不仅阐明真核生物进化过程中细胞生物学过程的差异，而且阐明它们的相似之处。